top of page
Our Consortium
CERTAINTY has been established to harness a wide range of expert knowledge with the goal of creating a lasting VT ecosystem to aid patients who qualify for CAR T cell therapy. To ensure comprehensive coverage of CERTAINTY's objectives, various esteemed European institutions, small and medium enterprises (SMEs), patient organisations, and industry players, each bringing different areas of expertise, have collaborated to form this consortium.
Insights Shared by Team Members
Dr. Kristin Reiche, FHG IZI, CERTAINTY Coordinator
“From a computer science perspective, we view the patient's unique CAR T cells as a living therapy, i.e., as a biological system. As CAR T cells interact with a living system, namely the patient, approaches to personalised medicine require rethinking and innovation. Thus, our goal is to combine the patient's unique molecular, cellular, and clinical data with the CAR T cell product's unique molecular and cellular data, paving the way for personalised therapy response and risk profiles. Given the current emerging role of CAR T cells in multiple myeloma, it serves as a crystallisation point for other malignancies with comparable treatment paradigms.”
Fraunhofer - Project coordinator
Germany
Leipzig University
Germany
Singleron Biotechnologies
Germany
Collaborate Project Management
Germany
Myeloma Patients Europe
Belgium
TriNetX Oncology
Germany
Masaryk University
Czechia
ITTM
Luxembourg
University Hospital Würzburg
Germany
Institut Curie
France
University of Namur
Belgium
University Medical Center Utrecht
Netherlands
Charité – Universitätsmedizin Berlin
Germany
EBMT
Netherlands
HealthTree Foundation
United States
Roche - Associated Partner
Switzerland
HZDR
Germany
bottom of page